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Nitric oxide down-regulates connective tissue growth factor in identified: the constitutive, calmodulin-dependent neu-
rat mesangial cells. ronal NOS (nNOS; NOS 1) and endothelial NOS (eNOS;
Background. Nitric oxide (NO) exerts complex regulatory NOS 3), and the inducible, calmodulin-independentactions on mesangial cell (MC) biology, such as inhibition of
NOS (iNOS; NOS 2), which can be expressed in severalproliferation, adhesion or contractility and induction of apopto-
cell types, among them macrophages and mesangial cells.sis. In our previous studies the NO-donor S-nitroso-glutathione
(GSNO) was found to be a potent inhibitor of MC growth. In the healthy human kidney nNOS is localized in the
This effect was mediated at least in part by inhibitory effects macula densa and the efferent arterioles, eNOS in the
of GSNO on the transcription factor early growth response glomerular endothelium and the afferent and efferentgene-1 (Egr-1) [10]. We therefore were interested in the regula-
arterioles, and an expression of iNOS is not or onlytion of gene expression in MC after treatment with NO.
Methods. To identify the genes that are regulated by NO in barely found [1–3]. The inhibition of NOS by NG-mono-
MC, gene expression was analyzed by representational differ- methyl-l-arginine (L-NMMA) or N-nitro-l-arginine
ence analysis. Expression of connective tissue growth factor methyl ester (L-NAME) in healthy rats causes glomeru-
(CTGF) was studied by Northern and Western blot analyses.
lar hypertension, glomerulosclerosis, matrix expansionResults. Cultured rat MCs treated with GSNO for 8 hours
and increased intraglomerular platelet aggregation [4, 5].were compared with unstimulated MCs and the CTGF mRNA
was found to be down-regulated. The down-regulation was Whereas NOS inhibition ameliorates the course of glo-
dose-dependent and transient, with a maximum inhibition seen merulonephritis and arthritis in MRP lpr/lpr mice, a
after 6 hours. In parallel, down-regulation of CTGF protein model of lupus nephritis [6], positive effects of NO haveby GSNO was observed by Western blot analysis. Other NO-
been described in a variety of other models of inflamma-donors such as S-nitroso-N-acetyl-D,L-penicillamine and sperm-
tory kidney diseases. In rat nephrotoxic serum nephritisine-NO showed similar effects. The induction of the inducible
NO-synthase by TNF-, IL-1 and LPS provoked a transient (anti-glomerular basement membrane nephritis) the in-
down-regulation of CTGF mRNA, an effect that could be hibition of NO production by L-NMMA leads to in-
partially overcome by pretreatment with the NOS-inhibitor
creased proteinuria, systemic and glomerular hyperten-N-nitro-l-arginine methyl ester. The observed NO-effect could
sion and worsening of the disease process [7]. NO is alsobe simulated by treatment with the stable cGMP analog 8br-
cGMP, and was abolished by blocking the guanylyl cyclase protective in the subtotal nephrectomy model, where
with the inhibitor NS2028. l-arginine supplementation prevents the development
Conclusion. NO acts as a strong repressor of CTGF expres- of glomerulosclerosis [8].sion in cultured rat MC. Thus, in addition to its antiproliferative
Glomerular mesangial cells (MC), a key cell type in theeffects, NO potentially exerts antifibrotic activity by down-
orchestration of glomerular inflammation and ultimatelyregulation of CTGF.
fibrosis, are capable of producing high amounts of NO
by an iNOS and are therefore a source as well as a main
Nitric oxide (NO) is a small gaseous molecule pro- target of NO in inflammatory glomerular diseases. The
duced in vivo by NO synthases (NOS) from the substrate following effects of NO on glomerular MC have been
l-arginine. Three different NOS isoforms have been described. Coincubation experiments have shown that
NO released by endothelial cells leads to cyclic 3,5-
guanosine monophosphate (cGMP) accumulation in MCKey words: representational difference analysis, cell proliferation, ad-
hesion, apoptosis, fibrosis and NO, S-nitroso-glutathione. and inhibits angiotensin II-induced contraction [9]. Sev-
eral studies showed that NO inhibited the proliferationReceived for publication May 29, 2001
of MC [9–11]. Furthermore, NO inhibits the adhesion ofand in revised form November 15, 2001
Accepted for publication March 8, 2002 MC to extracellular matrix proteins [12], as well as the
expression of intracellular adhesion molecule-1 (ICAM-1) 2002 by the International Society of Nephrology
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[13] and the synthesis of the matrix proteins collagen and tinued for another 20 minutes, followed by filtration of
fibronectin [14]. Therefore, NO exerts anti-mitogenic as the precipitate. GSNO was washed once with 80% ace-
well as anti-fibrotic actions on glomerular MC. tone, two times with 100% acetone, and finally, three
To further investigate these actions, we examined times with diethyl ether, and dried under vacuum. Freshly
modifications of gene expression patterns in cultured rat synthesized GSNO was characterized by high-pressure
MC after stimulation with NO. The NO donor S-nitroso- liquid chromatography (HPLC) analysis and ultraviolet
glutathione (GSNO) was used as a source for NO. To (UV) spectroscopy. S-nitroso-N-acetyl-dL-penicillamine
identify differentially expressed genes, a polymerase (SNAP) was purchased from Alexis (Gru¨nberg, Germany),
chain reaction (PCR) based subtractive hybridization spermine-NO, 8bromo-cGMP (8br-cGMP) and tumor
method was used, the representational difference analy- necrosis factor- (TNF-) were from Sigma (Deisen-
sis (RDA) [15], that was able to identify connective tissue hofen, Germany), heparin was from Roche (Mannheim,
growth factor as a gene, which is down-regulated by NO. Germany), interleukin-1 (IL-1), NS2028 and lipopoly-
Connective tissue growth factor (CTGF) is a member saccharide (LPS) were from Calbiochem (Merck, Darm-
of the CCN (Cyr 61/Cef-10, CTGF/Fisp-12, Nov) imme- stadt, Germany).
diate early gene family [16] and is considered to be criti-
cally involved in fibrosis as a downstream mediator of Growth factors and antibodies
transforming growth factor-beta (TGF-) [17, 18]. Hu- Recombinant human CTGF, pre-immune chicken IgY
man CTGF was identified as a mitogen found in the (pCIgY13) and neutralizing chicken anti-CTGF anti-
conditioned medium of human umbilical vein endothe- body (pIgY13) were provided by FibroGen Inc. (South
lial cells (HUVECs) immunoreactive with polyclonal an- San Francisco, CA, USA). Recombinant human CTGF
tibodies raised against a preparation of platelet-derived was generated using a baculovirus expression system and
growth factor (PDGF) [19]. The 38 kD protein is cys- purified by heparin-Sepharose affinity chromatography
teine-rich, secreted and extracellular matrix associated as described previously [21]. Peak fractions containing
[20]. The biological functions of CTGF have been shown recombinant human CTGF (rhCTGF) were determined
to be quite diverse. Earlier studies described mitogenic by immunoblotting and Coomassie staining of sodium
and chemotactic activities of CTGF on fibroblasts, and dodecyl sulfate (SDS)-polyacrylamide gels. Neutraliz-
an important role in wound healing was suggested as well ing anti-CTGF antibody was raised in chicken by immu-
[19, 21, 22]. Furthermore, CTGF was found to be involved nization with purified baculovirus-derived, full-length
in the proliferation and migration of vascular endothelial rhCTGF protein as previously described, and was subse-
cells and seems to play a central role in the growth and
quently affinity purified through a rhCTGF-Sepharose
differentiation of chondrocytes [23, 24]. CTGF expression
column.has been associated with various fibrotic diseases such
as scleroderma, lung fibrosis or arthrosclerosis [25]. In Mesangial cell culture
the kidney increased CTGF expression was noted in hu-
Glomeruli from kidneys of male Sprague-Dawley ratsman diabetic nephropathy [26] as well as in various animal
(200 g) were isolated and glomerular outgrowth and sub-models, like streptozotocin-induced diabetes mellitus,
sequent subculturing of MC was performed as describedanti-Thy-1.1-nephritis and renal fibrosis disease models
previously [31]. MC were maintained in Dulbecco’s mod-including the 5/6-nephrectomy [17, 27, 28]. In glomerular
ified Eagle’s medium (DMEM) supplemented with 10%MC CTGF was found to be up-regulated in a variety of
heat-inactivated (56C, 30 min) FCS, 50 U/mL penicillin,profibrotic conditions, such as, after exposure to TGF-,
50 g/mL streptomycin, 2 mmol/L glutamine, and 5high glucose or stretch [18, 27, 29].
g/mL insulin in a 95% air-5% CO2 humidified atmo-Given the presumed critical involvement of CTGF in
sphere at 37C. MC were used for experiments betweenrenal fibrosis, we performed a more detailed analysis of
passages 8 and 20. The cell viability was measured bythe nature and kinetics of the NO-induced decrease of
the trypan blue-exclusion test, if indicated.CTGF-mRNA level revealed by RDA.
RNA extraction
METHODS Mesangial cells were grown in 10 cm dishes until sub-
Reagents confluency. After stimulation with GSNO/GSH, SNAP,
Spermine-NO, cytokines or 8br-cGMP, cells were washedS-nitroso-glutathione (GSNO) was synthesized as de-
once in cold phosphate-buffered saline (PBS; 4C) andscribed previously [30]. Briefly, glutathione was dissolved
total RNA was extracted by the method of Chomczyn-in 0.625 N HCl at 4C to a final concentration of 625
ski and Sacchi [32]. Poly-A RNA isolation from totalmmol/L. An equimolar amount of NaNO2 was added
RNA was achieved by use of oligo-dT coated polystyreneand the mixture was stirred for 40 minutes at 4C. After
the addition of 2.5 volumes of acetone, stirring was con- latex particles (Qiagen, Hilden, Germany). The quality
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of mRNA preparations was confirmed visually after elec- lon membranes (Amersham Life Science, Little Chal-
font, UK) as recommended by the company (Clontech).trophoresis in a 1% agarose-formaldehyde gel.
The membranes were air dried and hybridized with
Representational difference analysis [32P]dCTP labeled forward- and reverse-subtracted
cDNA probes of the GSNO-treated and untreated mRNAThe representational difference analysis of cDNA
(RDA) as described by Hubank and Schatz [15] was populations. Blots were exposed to Kodak Biomax MS
or MR films (Eastman Kodak Company, Rochester, NY,performed with the Clontech PCR-Select cDNA Sub-
traction Kit (Clontech, Palo Alto, CA, USA) according to USA) at 80C. Differentially expressed RNAs were
used for further tests in Northern blot.the manufacturer’s protocol. For this purpose, poly-A
RNA was extracted from GSNO-treated and control
Northern blot analysisMC and reverse transcribed into cDNA. The cDNA that
contains the specific (differentially expressed) transcripts For RNA analysis 10 g of total RNA from GSNO
or GSH stimulated MC were separated by electrophore-was termed “tester” and the reference cDNA “driver.”
The tester and driver cDNAs were digested by Rsa I, sis in a 1% agarose-formaldehyde gel. The RNA was
blotted from the gel onto nylon membranes (Amersham)a four-base-cutting restriction enzyme that yields blunt
ends. The tester cDNA was then subdivided into two and baked at 80C for two hours. Membranes were pre-
hybridized for 30 minutes at 68C in ExpressHyb hybrid-portions, and each was ligated with a different cDNA
adaptor. The two adaptors had stretches of identical ization solution (Clontech). cDNA hybridization probes
were labeled with [32P]dCTP using a random primersequence to allow annealing of PCR primers once the
recessed ends have been filled in. Two hybridizations labeling kit (Amersham). Hybridization was at 68C in
fresh ExpressHyb hybridization solution containing ra-were then performed. In the first, an excess of driver was
added to each sample of tester. The samples were then diolabeled cDNA probes at a concentration of 2 	 106
cpm/mL for one hour. Next, membranes were washedheat denatured and allowed to anneal. The concentration
of high- and low-abundance sequences was equalized several times with 2 	 standard sodium citrate (SSC)/
0.1% SDS, until the wash solution did not ray more thanamong the single strand molecules ligated to an adaptor
because reannealing is faster for the more abundant mol- the background. Blots were exposed to Kodak Biomax
MS or MR films (Eastman Kodak Co.) at 80C.ecules due to the second-order kinetics of hybridization.
At the same time, these molecules were significantly
Western blot analysisenriched for differentially expressed sequences. During
the second hybridization, the two primary hybridization Rat MC were cultured in DMEM medium containing
10% serum with or without 5 U/mL heparin to stabilizesamples and again an excess of driver were mixed to-
gether without denaturing. Now, only the remaining CTGF protein. Subconfluent cells were not stimulated
or stimulated with 500 mol/L GSNO or GSH once forequalized and subtracted single-strand tester cDNAs
could reassociate and form hybrid double-strand tester eight hours or repeatedly at 0 and 12 hours for a total
of 24 hours. The supernatants were harvested and ethyl-molecules with different ends, which correspond to the
sequences of the different adaptors. The entire popula- enediaminetetraacetic acid (EDTA; 1 mmol/L) and the
protease inhibitors phenylmethylsulfonyl fluoride (PMSF;tion of molecules was then subjected to PCR to amplify
the desired differentially expressed sequences. Only the 1 mmol/L), aprotinin (2 g/mL), leupeptin (2 g/mL)
and pepstatin (0.5 g/mL) were added. For some experi-molecules, which had two different adaptors, could be
amplified exponentially. These were the equalized, dif- ments heparin binding proteins were extracted from con-
ditioned medium with heparin-sepharose CL-6B beadsferentially expressed sequences. A secondary PCR am-
plification was performed using nested primers to further (Amersham-Pharmacia, Roosendaal, The Netherlands)
for two hours at 4C. Bound proteins were eluted byreduce any background PCR products and enrich for
differentially expressed sequences. boiling in 2 	 SDS sample buffer and resolved on a 8%
SDS polyacrylamide gel and subsequently transferred to
Cloning of PCR fragments a nitrocellulose membrane (Schleicher & Schuell, Das-
sel, Germany). Membranes were blocked in phosphate-The PCR products resulting after the subtraction pro-
cedure were blunt-end cloned into pCR-Script SK() buffered saline (PBS) containing 0.5% Tween 20 and
5% bovine serum albumin (BSA) and incubated withvector (Stratagene, La Jolla, CA, USA) and transfected
in E. coli XL1-Blue MRF’ supercompetent bacteria chicken anti-hCTGF antibody (pIgY13) at 0.5 g/mL
in blocking buffer, followed by horseradish peroxidase(Stratagene).
(HRPO)-conjugated rabbit anti-chicken antibody (Zy-
Dot blot analysis med, San Francisco, CA, USA) in blocking buffer. Im-
mobilized antibodies were visualized with the enhancedTo identify differentially expressed RNAs, equal
amounts of cloned cDNAs were dotted twice onto ny- chemiluminescence system (ECL; NEN Life Science, Za-
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Fig. 1. Dose-dependent and transient down-regula-
tion of CTGF by GSNO. MC were grown in medium
containing 10% FCS until subconfluency and treated
with increasing concentrations of GSNO (50 mol/L,
100 mol/L, 250 mol/L, 500 mol/L, 1 mmol/L) for
8 hours (A) or with 500 mol/L GSNO for 0.5, 3, 6,
12, 24 and 48 hours (B). Control cells were treated
with equimolar amounts of GSH for the same time
intervals. RNA was extracted and 10 g total RNA
per lane were size fractionated on a 1% agarose gel.
Blots were stained with methylene blue to control
for equal loading and probed with a cDNA for CTGF
radiolabeled by random priming. Abbreviations are
in the Appendix.
ventem, Belgium) according to the manufacturer’s in- Northern blot analysis. Of the 51 identified clones, 12
(24%) were confirmed to be differentially expressed.structions and exposure to X-Omat blue XB-1 films (Ko-
dak, NEN Life Science). One of the identified genes was CTGF, which was down-
regulated by GSNO.
RESULTS Down-regulation of CTGF mRNA by GSNO is dose-
and time-dependentIdentification of CTGF as a NO-regulated gene in
glomerular mesangial cells To investigate whether the down-regulation of CTGF
mRNA by GSNO is time- and dose-dependent, increas-To identify genes that are differentially expressed after
NO induction, the representational difference analysis ing concentrations of GSNO (50 mol/L, 100 mol/L,
250 mol/L, 500 mol/L and 1 mmol/L) and harvested(RDA) was used, which is a polymerase chain reaction
(PCR)-based subtractive hybridization method [15]. cells were tested after different time points after stimula-
tion (0.5, 3, 6, 12, 24 and 48 hours). Control MC wereRDA has advantages over conventional subtractive hy-
bridization methods, because the procedure is less time treated with an equimolar amount of glutathione sulfhy-
dryl (GSH). The expression of CTGF mRNA decreasedconsuming and allows the identification of low abun-
dance genes. For this purpose MC were stimulated for with increasing concentrations of GSNO, beginning at
250mol/L and reaching a minimum of CTGF transcripteight hours with 500 mol/L GSNO, a concentration
which inhibits MC proliferation but is not toxic and does levels at the highest tested GSNO concentration of 1
mmol/L (Fig. 1A). GSH alone had no effect on CTGFnot induce apoptosis of MC cultured in the presence of
10% fetal calf serum (FCS) [10], and compared them expression. Furthermore, MC treated with 500 mol/L
GSNO and harvested after different time points showedwith untreated cells as control. Poly A-RNA from con-
trol and GSNO-treated cells was isolated, reverse tran- a transient down-regulation of CTGF mRNA as early
as three hours after GSNO-treatment with an expressionscribed into cDNA and subtracted as described earlier
in this article. After the RDA procedure the PCR ampli- remaining low after six hours. After 12 hours CTGF
mRNA levels had returned to baseline. GSH again didfication products were cloned, representing potentially
GSNO-regulated genes. The differential expression of not significantly affect CTGF-expression (Fig. 1B). The
data were confirmed in four independent experiments.the identified mRNAs was confirmed by dot blot and
Keil et al: NO downregulates CTGF in mesangial cells 405
Fig. 2. Repeated GSNO-treatment leads to prolonged down-regulation of CTGF mRNA and CTGF mRNA is down-regulated by different NO-
donors. (A) MC were grown in medium containing 10% FCS until subconfluency and not treated (lane 1), treated once (lanes 2 and 3) or repeatedly
every 9 hours (lane 4) with 500 mol/L GSNO for 6 or 24 hours. MC were grown in medium containing 10% FCS until subconfluency and treated
with 500 mol/L GSNO, 500 mol/L SNAP or 250 mol/L SpNO, respectively, for 6, 10, or 24 hours. Control cells were not treated, treated with
500 mol/L GSH or with ethanol, the solvent for SNAP (B). RNA was extracted and 10 g total RNA per lane was size fractionated on a 1%
agarose gel. Blots were stained with methylene blue to control for equal loading and probed with a cDNA for CTGF radiolabeled by random
priming. Abbreviations are in the Appendix.
Since CTGF expression had returned to control levels 10 and 24 hours. As controls MC were treated with
the appropriate amount of GSH, with the appropriateafter 12 hours of GSNO stimulation, we tested whether
this was due to subsiding NO release from GSNO by volume of ethanol, the dissolving agent of SNAP or left
untreated. Northern blot analysis showed that all threerepeatedly adding GSNO to cultured rat MC. Repeated
NO donors were able to down-regulate CTGF mRNAaddition of GSNO at 0, 9 and 18 hours led to a prolonged
(Fig. 2B). However, there were differences in the kineticsinhibition of CTGF mRNA expression for 24 hours (Fig.
of down-regulation, most likely reflecting differences in2A). The cell viability was confirmed by trypan blue-
the kinetics of NO release from the different NO donors.exclusion tests. We therefore concluded that the continu-
ous presence of NO leads to sustained down-regulation
Induction of mesangial cell iNOS leads toof CTGF.
down-regulation of CTGF mRNATo test whether the effect was specific for GSNO, the
question of whether other NO-donors like spermine-NO Since external application of NO donors is a very arti-
ficial situation, we investigated whether NO release by(SpNO) or SNAP also would affect CTGF expression
was addressed. MC were treated with 500 mol/L of induction of mesangial iNOS could down-regulate CTGF
mRNA. MC were stimulated with 25 ng/mL TNF-, 250GSNO and SNAP and with 250 mol/L of SpNO for 6,
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Fig. 3. Induction of iNOS leads to down-reg-
ulation of CTGF mRNA. MC were grown in
medium containing 10% FCS until subcon-
fluency, serum starved for 48 hours in medium
containing 0.4% FCS and treated with 25
ng/mL TNF-, 250 U/mL IL-1 and 10 g/mL
LPS for 2, 4, 6, 8, 10 and 24 hours (lanes 3
to 14). L-NAME 1 mmol/L was added for the
same time intervals to inhibit the induced NO-
production (lanes 9 to 14) and in part attenu-
ated the down-regulation of CTGF mRNA.
Serum-starved control cells were not treated
and harvested after 0 and 24 hours (lanes 1
and 2). RNA was extracted and 10 g total
RNA per lane was size fractionated on a 1%
agarose gel. Blots were stained with methyl-
ene blue to control for equal loading and
probed with cDNAs for iNOS ( ) and CTGF
() radiolabeled by random priming.
U/mL IL-1 and 10 g/mL LPS, a mixture that has been treatment of MC with the stable cGMP-analog 8br-
shown to induce iNOS [33], for 2, 4, 6, 8, 10 and 24 cGMP (1 mmol/L) was able to down-regulate CTGF
hours. To verify that the observed effects were due to mRNA. Northern blot analysis showed that 8br-cGMP
the release of NO and not to direct cytokine actions, had comparable effects on CTGF mRNA expression
MC were additionally treated with 1 mmol/L L-NAME, as GSNO (Fig. 4A). Additionally, the inhibition of the
a structural analog of l-arginine, which inhibits or im- guanylyl cyclase, which leads to a suppression of cGMP
pairs the NO production by NOS. Stimulation of MC production by this enzyme, abolished the effect of GSNO
with TNF-, IL-1 and LPS increased iNOS mRNA on CTGF gene regulation. MC were treated with 5
expression; the effect was first evident after two hours mol/L of the guanylyl cyclase inhibitor NS2028 six
and maximum induction was seen after 10 hours. Accord- hours prior to the addition of 500 mol/L GSNO for a
ingly, down-regulation of CTGF mRNA was observed further six hours. As shown by Northern blot analysis,
beginning four to six hours after stimulation and reaching blocking of cGMP generation could overcome the down-
a maximum between six and ten hours. Inhibition of NO regulating effect of GSNO on CTGF mRNA expressionproduction by L-NAME led to a significant, but not
(Fig. 4B). This suggests that the observed effects ofcomplete attenuation of CTGF down-regulation (Fig. 3).
GSNO on CTGF are mediated by generation of cGMP.Since L-NAME is a competitor to l-arginine and not a
direct NOS inhibitor, a complete inhibition of the ob- CTGF protein in the supernatant of MC is
served NO effect was not expected. down-regulated after treatment with GSNO
Effect of NO on CTGF gene regulation is mediated To investigate whether the observed effect of NO on
by cGMP CTGF mRNA expression could be seen at the protein
level, Western blot analysis was performed (Fig. 5).Nitric oxide activates the soluble form of guanylyl
cyclase to generate cGMP. We therefore tested whether CTGF is a secreted protein that binds to the extracellular
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Fig. 5. CTGF protein is down-regulated by GSNO. MC were grown
in medium containing 10% FCS and 5 U/mL heparin until subconfluency
and treated with 500 mol/L GSNO once for 8 hours and twice at 0
and 12 hours, for a total of 24 hours. Control cells were not treated or
treated with 500 mol/L GSH in the same manner. Proteins in the
supernatants were harvested and heparin-binding proteins were ex-
tracted with heparin-sepharose CL-6B beads. Bound proteins were
eluted and resolved on an 8% SDS polyacrylamide gel. Blots were
stained with chicken anti-hCTGF antibody, followed by HRPO-con-
jugated rabbit anti-chicken antibody. Human recombinant CTGF
(hrCTGF) was loaded (lane 1) to confirm the specific signal for CTGF
obtained with the chicken anti-hCTGF antibody.
inflammatory processes. In addition to their capacity of
antigen presentation, phagocytosis, clearance of macro-Fig. 4. The down-regulation of CTGF mRNA is mediated by cGMP.
MC were grown in medium containing 10% FCS until subconfluency molecules and regulation of glomerular filtration, MC
and treated with 1 mmol/L 8br-cGMP for 6 and 10 hours (A), or with
are able to proliferate and to produce and deposit extra-5 mol/L of the guanylyl cyclase inhibitor NS2028 for 6 hours followed
cellular matrix molecules, which can lead to sclerosis andby the addition of 500 mol/L GSNO for 6 hours (B). Control cells
were treated with an equal amount of the inhibitor NS2028 alone or fibrosis [34]. In vitro studies have shown that NO inhibits
left untreated. RNA was extracted and 10 g total RNA per lane was
MC proliferation and reduces matrix production andsize fractionated on a 1% agarose gel. Blots were stained with methylene
adhesion [10, 12, 14]. Since it is known that NO, in addi-blue to control for equal loading and probed with cDNA for CTGF
radiolabeled by random priming. tion to exerting regulatory functions on glomerular he-
modynamics, can lead to direct alteration of gene expres-
sion, we tried to identify the genes regulated by NO in
matrix, but is also found in the culture medium. Although glomerular MC. For this purpose, the RDA method was
the half-life of the protein is not exactly known, it seems employed, which is a PCR-based subtractive hybridiza-
to be short, complicating the detection of the protein. tion method [15].
Since heparin is able to stabilize CTGF protein, it was A transient down-regulation of CTGF was observed
added to the culture medium. MC were treated once by GSNO with levels coming back to baseline by 12
with 500 mol/L GSNO for eight hours or repeatedly to 24 hours, whereas GSH had no influence on gene
at 0 and 12 hours for 24 hours, and supernatants were expression. This transient down-regulation most likely
collected. CTGF protein was purified from equal is due to the release kinetic of GSNO. Since NO itself
amounts of supernatants by heparin sepharose beads. is an unstable radical with a short half-life of a few sec-
Heparin bound protein was eluted by boiling in SDS onds, the duration of the NO effect elicited by a certain
sample buffer, resolved on SDS-PAGE, and Western NO-donor depends on the release kinetics of the specific
blot analysis was performed. Strong down-regulation of substance. These release kinetics of NO-donors are de-
CTGF protein was evident after eight hours as well as pendent on various conditions such as pH, temperature,
after 24 hours of treatment with GSNO.
buffer composition and others. Moreover, half-lives vary
with the method used for their analysis. Taking these
DISCUSSION restrictions into account, the half-life of GSNO is esti-
mated to be approximately ten hours [35]. To testMesangial cells are a source of as well as the main
target cells of NO. They are key cells in glomerular whether the short half-life of GSNO is responsible for
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the observed transient down-regulation of CTGF, we with 30 and 300 mg/kg L-NAME [37]. The incomplete
L-NAME-mediated competition of CTGF–down-regu-repeatedly added GSNO to the cultured MC. As ex-
pected, down-regulation of CTGF was maintained for lation after generation of the endogenous NO also could
be explained by additional effects of the cytokine mixmore than 24 hours, whereas the expression of CTGF
after a single administration of GSNO had returned to other than stimulation of iNOS.
Some actions of NO are mediated by generation ofbaseline by 12 to 24 hours. MC could not be stimulated
for prolonged periods of time, since apoptotic and toxic cGMP. Addition of the stable cGMP analog 8br-cGMP
led to a comparable down-regulation of CTGF mRNAevents occurred after 48 hours. To confirm that our cells
were still alive after 24 hours of repeated GSNO-treat- after six hours as the addition of NO-donors, indicating
that CTGF down-regulation could be accounted for byment, a trypan blue-exclusion test was performed and
untreated cells were compared with stimulated cells. No an increase in cellular cGMP-concentration. To confirm
these data, we blocked the generation of cellular cGMPdifference between the repeatedly treated and untreated
cells was observed. The NO-donors Sp-NO and SNAP by NS2028, an inhibitor of the guanylyl cyclase. NS2028
alone led to a small decrease of CTGF mRNA level, buthad similar effects on CTGF expression as GSNO, which
indicates that the down-regulation is not only GSNO- as expected, the down-regulating effect of GSNO on
CTGF expression was nearly completely abolished bymediated, but is indeed NO-mediated. SNAP showed
an even stronger down-regulation of CTGF mRNA with the inhibition of the guanylyl cyclase, validating that the
cGMP signaling pathway is used for the down-regulationa similar time course as GSNO. The observed shorter
down-regulation of CTGF by Sp-NO than that seen with of CTGF.
We demonstrated that GSNO not only down-regulatesGSNO or SNAP is in agreement with its faster release
kinetic (as compared to GSNO and SNAP). CTGF mRNA, but also CTGF protein. As described in
the literature, the protein detected in our culture super-Since exogenous addition of NO is a very artificial
situation, we also tested whether induction of endoge- natant as well as the recombinant human CTGF sepa-
rated at two bands of around 36 and 38 kD [18]. Bothnous MC iNOS would be sufficient to reproduce the
inhibitory effects of NO (donors) on CTGF mRNA by molecular weight forms of CTGF followed the same
expression pattern and showed the same down-regula-stimulating MC with TNF-, IL-1 and LPS. A strong
induction of iNOS was detected by these cytokines com- tion after GSNO treatment. CTGF protein levels were
significantly decreased by GSNO, rendering NO one ofbined with bacterial endotoxin and concomitant down-
regulation of CTGF mRNA was seen. We observed a the strongest inhibitors of CTGF expression. For a better
detection of the protein in some experiments our culturetime lag of only two hours between the first appearance
of iNOS mRNA and the decrease of CTGF mRNA. To medium was supplemented with heparin, because hepa-
rin binds to CTGF and stabilizes the protein [20].prove that the down-regulation of CTGF was indeed a
consequence of increase in NO-production by iNOS and Heparin is known to be anti-mitogenic [38], but the con-
centration used was very low and had no evident antipro-not a direct effect of the cytokine mix, the competitive
NOS-inhibitor L-NAME was included in a control ex- liferative effect on MC. Furthermore, we checked whether
heparin itself could have an influence on CTGF mRNAperiment. The down-regulation of CTGF was significantly
attenuated, although not entirely prevented. Because expression in the absence and presence of GSNO. There
was no difference in the expression pattern of CTGF withL-NAME is only a competitor to the substrate l-arginine
and not a direct inhibitor of the enzyme, a high excess of and without heparin before and after GSNO stimulation
(data not shown).competitor would be necessary to inhibit NO-production
completely. To achieve this end, 1 mmol/L L-NAME Taken together, our findings identify NO as a potent
inhibitor of CTGF-expression in MC. CTGF expressiondid not seem to be enough; however, higher concentra-
tions of L-NAME would change the pH of the culture is increased by various stimuli (TGF-1, TGF-2, TGF-,
BMP2, EGF, dexamethasone, high glucose, conditionedmedium and thus influence the experimental conditions
by itself. Other groups reported similar competition rates monocyte medium, and mechanical strain), but to date
only two inhibitors of CTGF expression have been iden-when using L-NAME as an inhibitor. Dulak et al stimu-
lated the iNOS of vascular smooth muscle cells with tified: TNF- and cAMP [18]. The inducing effect of
dexamethasone on CTGF expression in mouse fibro-IL-1 and showed an up-regulation of vascular endothe-
lial growth factor (VEGF) by NO. Additional supple- blasts was attenuated by TNF- [39]. TNF- also has
been shown to down-regulate CTGF-expression in bo-mentation with 2 to 5 mmol/L L-NAME decreased the
IL-1 up-regulated VEGF synthesis by only 30 to 40% vine endothelial cells, fibroblasts and smooth muscle cells
[40]. Interestingly, TNF- can induce iNOS expression,[36]. Gavin et al, who studied the VEGF mRNA increase
in rat skeletal muscle in response to a single acute exer- and therefore it is possible that the observed CTGF
down-regulation by TNF- is mediated at least in partcise bout, could attenuate this exercise-induced increase
in VEGF mRNA by approximately 50% by treatment by the induction of an iNOS and subsequent generation
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of NO. Another inhibitory effect has been described in tion of fibrosis and sclerosis, where CTGF seems to play
a key role. The ability of NO to down-regulate CTGFnormal rat kidney fibroblasts, where raised cAMP levels
or cAMP analogs inhibited the induction of CTGF by suggests that NO could play an important role in pre-
venting or ameliorating fibrotic processes, when deliv-TGF- [41]. In this context it should be mentioned again
that our findings indicate the ability of cGMP, which ered to the right place in the appropriate concentration.
Our findings could have important implications for un-is raised after NO generation, to down-regulate CTGF
mRNA in MC. derstanding the pathogenesis as well as for the treatment
of renal fibrosis, where regulated production of NO byNitric oxide is able to regulate not only CTGF, but
also various other genes, many of which are compounds intrinsic cells, such as MC, or controlled exogenous deliv-
ery of NO could ameliorate or prevent glomerular orof the extracellular matrix or are associated with it. In
dermal fibroblasts it was shown that the NO-donor so- interstitial fibrosis, scarring and ultimately loss of func-
tion. Moreover, our findings may add to the understand-dium nitroprusside (SNP) suppresses collagen produc-
tion [42]. This inhibition was dependent on the genera- ing of other fibrotic diseases, like atherosclerosis, where
endothelial dysfunction with a decrease in NO-produc-tion of cGMP. Chronic inhibition of NOS by L-NAME
in mice induces an early activation of the collagen I tion could have a direct impact on CTGF-expression and
consecutive deposition of fibrotic material.gene in afferent arterioles and glomeruli, and leads to
deposition of collagen I and the development of renal
vascular fibrosis [43], demonstrating the antifibrotic ACKNOWLEDGMENTS
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